Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Gentbrugge – page 77

1 787 clinical trials in Gentbrugge, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gentbrugge at a glance
1 787
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 787 trials in Gentbrugge

Open in trial search

Study on Luspatercept for Patients with Lower-risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Celgene Corp.

B-cell lymphoma

Not recruiting

Study of Glofitamab, Atezolizumab, and Polatuzumab Vedotin for Adults with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Guselkumab and Golimumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Study of Imetelstat in Patients with Low or Intermediate Risk Myelodysplastic Syndromes (MDS) Refractory to Erythropoiesis-Stimulating Agents

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Imetelstat Sodium
  • Sponsor:Geron Corp.

Fungal infection

Not recruiting

Study on Rezafungin to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fluconazole
  • Sponsor:Mundipharma Research Limited

Study of Tepotinib and Osimertinib for Patients with Advanced or Metastatic Lung Cancer Resistant to Osimertinib Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:Merck Healthcare KGaA

Study of Tepotinib for Patients with Advanced Lung Cancer with MET Exon 14 Skipping Alterations or MET Amplification

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tepotinib
  • Sponsor:Merck Healthcare KGaA

Study on Long-term Safety and Efficacy of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy Using a Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Argenx

Study on the Effectiveness and Safety of Epcoritamab Alone or with Lenalidomide for Patients with Diffuse Large B-Cell Lymphoma Who Cannot Use Anthracyclines

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with a Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of 19CP02 for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:19Cp02
  • Sponsor:Lakefront Biotherapeutics

IgA nephropathy

Not recruiting

Study on the Effects of Atacicept in Adults with IgA Nephropathy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atacicept
  • Sponsor:Vera Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Gentbrugge

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) medication management in primary care settings. This research examines optimal strategies for reducing long-term PPI use in patients without clear medical necessity.

  • Functional Dyspepsia
  • Gastroesophageal Reflux
  • Chronic Heartburn Management

The study compares various deprescribing approaches, including on-demand PPI use and alternative treatments with alginate formulations, aiming to establish more effective medication management protocols for patients with chronic digestive conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.